Abstract
Mesothelioma is a rare and aggressive tumor originating from the serosal
lining of the pleural, peritoneal and pericardial cavities. There are
very few cases diagnosed with malignant peritoneal mesothelioma reported
in childhood. Thanks to the developments in the field of immunotherapy,
the prognosis of the disease has improved with the addition of the
immune check point inhibitor, an anti-programmed death-1 monoclonal
antibody, nivolumab to the treatment of MPM. In the treatment of our
case who was diagnosed with diffuse malignant peritoneal mesothelioma at
a very early age; cytoreductive surgery, hyperthermic intraperitoneal
chemotherapy, platinum and pemetrexed combination chemotherapy and
nivolumab were used. Our patient, who has been on nivolumab therapy for
14 months and has been followed up for 20 months since her diagnosis, is
still in remission. This case supports the utility of nivolumab in
pediatric MPM.